Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05864391 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT05864391 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 40 participants.
The verdict
NCT05864391, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the safety, tolerability, and PK (measurement of drug activity in the body over time) of AZD7503 injected subcutaneously, and compared to placebo, in participants with suspected NASH, a type of liver disease.
Interventions
- DRUG AZD7503
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-03-31 |
| Est. Completion | 2024-03-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05864391
The ClinicalTrials.gov registry entry for NCT05864391 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD7503 is the first listed.
NCT05864391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05864391 about?
NCT05864391 is a clinical study titled "A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.". The purpose of this study is to measure the safety, tolerability, and PK (measurement of drug activity in the body over time) of AZD7503 injected subcutaneously, and compared to placebo, in participants with suspected NASH, a type of liver disease.
What is the current status of trial NCT05864391?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-03-31. Estimated completion is 2024-03-20.
What interventions are being tested in trial NCT05864391?
The interventions under investigation include: AZD7503 (DRUG).
Who is sponsoring clinical trial NCT05864391?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.